ClinicalTrials.gg
CompletedNCT04410198Updated Sep 13, 2022Results posted

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

A Phase 3 interventional study of Roxadustat in Anemia Associated With End Stage Renal Disease (ESRD), sponsored by FibroGen. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
15th of 43
203 · median 154
Started
2020
with 2 others
Phase 3
25 of 43
1 open now
Registered
29th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 15th largest by enrollment, is one of 3 that started in 2020, is one of 25 in phase 3, and was the 29th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of Roxadustat dosing regimens among chronic dialysis participants converted from ESA therapy or who are ESA-naïve.

03

Conditions studied

  • Anemia Associated With End Stage Renal Disease (ESRD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving chronic dialysis for end stage renal disease (ESRD)
  • Vascular access must be a functioning native arteriovenous fistula or graft with adequate flow in the opinion of the investigator, or permanent tunneled catheter
  • Screening criteria (based on central lab value; measured within 10 days prior to initiating Roxadustat treatment: Participants converting from CERA: screening heamoglobin was between 9.0 to 12.0 g/dL; Participants initiating anemia treatment: \<10.0 g/dL
  • Ferritin ≥ 50 nanograms (ng)/milliliter (mL), Transferrin saturation (TSAT) ≥ 10% at screening
  • Participant's (ALT) and aspartate aminotransferase (AST) are ≤3 x (ULN), and total (TBL) is ≤1.5 x ULN at screening and prior to initiating roxadustat treatment.
  • Body weight between 45.0 to 160.0 kg

Key Exclusion Criteria:

  • Red blood cell (RBC) transfusion within 4 weeks prior to enrollment
  • Known history of myelodysplastic syndrome or multiple myeloma
  • Known hereditary hematologic disease or other known causes for anemia other than chronic kidney disease (CKD)
  • Known chronic inflammatory disease that is determined by the investigator to be the primary cause of anemia
  • Active or chronic gastrointestinal bleeding
  • Treated with iron-chelating agents within 4 weeks prior to enrollment
  • History of (NYHA) Class III or IV congestive heart failure
  • History of myocardial infarction (MI), acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (excluding vascular dialysis access stenosis/thrombosis) within 12 weeks prior to enrollment
  • Uncontrolled hypertension, in the opinion of the Investigator
  • Diagnosis or suspicion of renal cell carcinoma as shown on renal imaging performed within 24 weeks prior to enrollment
  • History of , except for cancers determined to be cured or in remission for ≥2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant requires roxadustat \<60 milligrams (mg)/week to maintain Hb levels, the dose frequency will be reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from CERA, the initial roxadustat dose will be based on the average prescribed CERA dose in the last 8 weeks prior to conversion. For participants with \<6 weeks of prior CERA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.

    Drug: Roxadustat

Interventions

  • Roxadustat will be administered per dose and schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Mean Hb Value ≥10 g/dL

    Percentage of participants with mean Hb value ≥10 g/dL, averaged from Week 16 through Week 24 has been reported. 95% confidence interval (CI) was calculated based on the normal approximation to the binomial distribution.

    Time frame: Week 16 through Week 24

  2. Mean Hb Change From Baseline to Average Hb From Weeks 16-24

    Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. Missing data was imputed using Monte Carlo Markov Chain (MCMC) imputation model.

    Time frame: Baseline, Weeks 16-24

07

Results

Posted Sep 13, 2022

Participant flow

Participant flow — Overall Study
MilestoneRoxadustat
Started203
Received at least 1 dose of study drug203
Full analysis set201
Completed166
Not completed37
Withdrew: Death10
Withdrew: Withdrawal by subject7
Withdrew: Transferred/relocation4
Withdrew: Kidney transplant9
Withdrew: Adverse event4
Withdrew: Physician decision2
Withdrew: Other than specified1

Outcome measures

PrimaryPercentage of Participants With Mean Hb Value ≥10 g/dL

Percentage of participants with mean Hb value ≥10 g/dL, averaged from Week 16 through Week 24 has been reported. 95% confidence interval (CI) was calculated based on the normal approximation to the binomial distribution.

Time frame:
Week 16 through Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Hb Value ≥10 g/dL
percentage of participantsRoxadustat
Percentage of Participants With Mean Hb Value ≥10 g/dL84.7 (79.1 to 90.2)
PrimaryMean Hb Change From Baseline to Average Hb From Weeks 16-24

Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. Missing data was imputed using Monte Carlo Markov Chain (MCMC) imputation model.

Time frame:
Baseline, Weeks 16-24
Reported as:
Mean · g/dL
Mean Hb Change From Baseline to Average Hb From Weeks 16-24
g/dLRoxadustat
Mean Hb Change From Baseline to Average Hb From Weeks 16-240.46 ± 1.007

Adverse events

Collected over Baseline up to 28 days post last dose of roxadustat (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat10/203 (4.9%)52/203 (25.6%)34/203 (16.7%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventRoxadustat
COVID-19Infections and infestations5/203
Acute myocardial infarctionCardiac disorders4/203
PneumoniaInfections and infestations4/203
SepsisInfections and infestations4/203
Cardiac arrestCardiac disorders3/203
AstheniaGeneral disorders3/203
Fluid overloadMetabolism and nutrition disorders3/203
DeathGeneral disorders2/203
HypoglycaemiaMetabolism and nutrition disorders2/203
SyncopeNervous system disorders2/203
Most frequent other events
Most frequent other events
EventRoxadustat
DiarrhoeaGastrointestinal disorders15/203
CoughRespiratory, thoracic and mediastinal disorders12/203
COVID-19Infections and infestations11/203

Baseline characteristics

The safety analysis set included all enrolled participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Roxadustat
Mean58.7 ± 14.13
Sex: Female, Male
Sex: Female, Male(Participants)Roxadustat
Female85
Male118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roxadustat
Hispanic or Latino31
Not Hispanic or Latino168
Unknown or Not Reported4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roxadustat
Race — Black or African American84
Race — American Indian or Alaska Native3
Race — Asian4
Race — Native Hawaiian or Other Pacific Islander3
Race — White105
Race — Other4
Baseline Hb
Baseline Hb(grams (g)/deciliter (dL))Roxadustat
Mean10.402 ± 0.8159
08

Study locations

9 sites
  • Investigational Site
    Englewood, Colorado 80110, United States
  • Investigational Site
    Caldwell, Idaho 83642, United States
  • Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Investigational Site
    Kalamazoo, Michigan 49009, United States
  • Investigational Site
    Tupelo, Mississippi 38801, United States
  • Investigational Site
    Saint Ann, Missouri 63074, United States
  • Investigational Site
    Las Vegas, Nevada 89106, United States
  • Investigational Site
    Sugar Land, Texas 77479, United States
  • Investigational Site
    Saint George, Utah 84790, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2021, 13 months.

Results were first posted in Sep 2022, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 13 months is below that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 1, 2020
StartActual
May 26, 2020
Primary completionActual
Jun 30, 2021
CompletionActual
Oct 11, 2021
Results first posted
Sep 13, 2022
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04410198
Lead sponsor
FibroGen
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
May 26, 2020
Primary completion
Jun 30, 2021
Completion
Oct 11, 2021
Results posted
Sep 13, 2022
Last update
Sep 13, 2022

Study contacts

Mark Eisner
study chair · FibroGen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion